Alvotech Reports Results of AVT04, a Proposed Biosimilar to Stelara in (AVT04-GL-101) PK Study for the Treatment of Plaque Psoriasis
Shots:
- The (AVT04-GL-101) PK study evaluates PK, safety, tolerability, and immunogenicity of AVT04 (SC, 45mg/0.5mL) vs US-licensed & EU-approved Stelara in 294 healthy adult patients at Australia & New Zealand
- The results showed bioequivalence of AVT04 to Stelara with no clinical safety differences @28wks. The results from the confirmatory efficacy & safety study for AVT04 are expected before the end of Q2’22
- On Dec 2021, Alvotech collaborated with Oaktree where the combined company’s securities are expected to be listed on NASDAQ under the symbol “ALVO”. Ustekinumab is a human IgG1k mAb that binds to the p40 protein subunit utilized by interleukin-12 and interleukin-23 cytokines with high specificity
Ref: Alvotech | Image: Alvotech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
